Copyright Primer and Tips for Authors

     Below are three interesting and useful blog posts and websites dealing with copyright issues.

     This blog provides legal primers on a variety of legal subjects, including the linked primer that provides an in-depth summary of United States copyright, fair use, and Digital Millenium Copyright Act (DMCA) issues. The primer concludes with some helpful hints concerning the oft-misunderstood fair use exceptions, and what individuals can do to minimize their risk of copyright liability:

"Use only as much of the copyrighted work as is necessary to accomplish your purpose or convey your message;

"Use the work in such a way that it is clear that your purpose is commentary, news reporting, or criticism;

"Add something new or beneficial (don't just copy it -- improve it!);

"If your source is nonfiction, limit your copying to the facts and data; and

"Seek out Creative Commons or other freely licensed works when such substitutions can be made and respect the attribution requests in those works."

  • Collectanea by the University of Maryland University College

     Pronounced kol-ek-tey-nee-uh, this blog is published by Georgia Harper, a scholar at UMUC's Center for Intellectual Property (CIP).  In it, Harper collects and discusses current copyright issues. Her latest post, Turnitin wins important victory in fight to combat plagiarism (and the bloat of copyright), is an excellent analysis of AV v. iParadigms, No. 07-0293, slip op. (E.D. Va Mar. 11, 2008), which involves the website Turnitin.com, which Harper says is "an application that teachers can use to compare their students' papers with Turnitin's database of previously compared papers and papers available from other sources to detect instances of suspicious similarity."

     This creative website, which is written by legal academics at Columbia Law School, is designed for authors and creators of works in the United States. It aims to provide individuals with information to help them retain their copyrights, or, in case they decide to license their rights to others, with information concerning how to obtain reasonable terms under that license. The website provides sample contracts for literary authors, photographers, journal manuscript authors, and others, and also useful information about royalty statements in author contracts. The website warns that it is specifically not intended for lawyers or other legal academics, and it should not be considered legal advice.  

Court Grants Martek Biosciences an Injunction Against Lonza, Nutrinova

    

This is from Martek Biosciences's (Columbia, MD) website:

"Martek Biosciences Corporation (NASDAQ: MATK) today announced that a judge in the United States District Court in Wilmington, Delaware, has ruled on various post-trial motions and will enter a permanent injunction in Martek's favor against the defendants in the patent infringement suit brought by Martek against Lonza, Ltd., Nutrinova Inc. and Nutrinova Nutrition Specialties & Food Ingredients GmbH. The suit involves Lonza's U.S. sale and use of a fatty acid product currently marketed under the brand name Lonza DHA for use in functional foods and dietary supplements and does not involve Martek's core infant formula patents.

"The judge upheld the October 2006 jury verdict that the defendants infringed all of the asserted claims of U.S. Patent Nos. 5,340,594 and 6,410,281 (the "'281 Patent") and that these patents were valid. The judge indicated that he will grant a permanent injunction against Lonza with respect to those two patents. The judge also upheld the jury verdict that Lonza had acted willfully in its infringement of the '281 Patent. Regarding the third patent involved in the case, U.S. Patent No. 6,451,567 (the "'567 Patent"), the judge reversed the jury verdict and found that there was insufficient evidence to show that the claims of this patent are enforceable against the defendants. Martek does not believe that this decision will have an adverse effect on the strength of the permanent injunction to be issued by the Court.

"Martek expects that Lonza will appeal the adverse decision against it to the U.S. Court of Appeals for the Federal Circuit. The permanent injunction will be in effect pending any appeal. Martek is considering the alternatives available to it regarding the '567 Patent."

Comments:

  • Please contact me if you would like a copy of the order/opinion, which should be available on PACER

  • Martek markets dietary supplements it calls life'sDHA™ and life'sARA™